Indaptus Therapeutics INDP Stock Is It a Good Entry Point Indaptus Therapeutics misses EPS views no revenue REFR Research shares fall 396 following Q2 2025 earnings release with no analyst consensus estimates available VOYAB Voya releases no formal quarterly earnings figures as investors track preferred stock yield stability Fidelity MSCI Consumer Discretionary Index ETF FDIS Positioning Amid Sticky Inflation and Geopolitical Energy Risks INGN Inogen posts narrower than expected Q4 2025 loss stock registers mild gain in daily trading